Potential Immunotherapeutic Targets on Myeloid Cells for Neurovascular Repair After Ischemic Stroke

Ziyu Zhu†, Li Zheng†, Yan Li†, Tingting Huang†, Yu-Chieh Chao†, Lijun Pan‡, Hui Zhu†, Yanhua Zhao†, Weifeng Yu⁎ and Peiying Li⁎

† Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China,
‡ Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

Neurological deficits and cognitive dysfunctions caused by acute ischemic stroke pose enormous burden to the stroke families and the communities. Restoration of the normal function of the neurovascular unit following ischemic stroke is critical for improving neurological recovery and cognitive functions after stroke. Recent evidence suggests that the myeloid cells including both the resident microglia and infiltrating monocytes/macrophages and neutrophils are highly plastic in response to the environmental cues. They intimately interact with multiple components of the neurovascular unit in response to the alarmins, danger associated pattern molecules (DAMPs) and other signals released from the ischemic brain. The aim of this review is to discuss the reciprocal interactions between the myeloid cells and the ischemic neurovascular unit during the late repair phase of cerebral ischemic stroke. We also summarize potential immunotherapeutic targets on myeloid cells and new therapeutic approaches targeting myeloid cells, such as cell transplantation, mitochondrial dynamic and extracellular vesicles-based therapy et al to enhance neurovascular repair for better stroke recovery.

Keywords: stroke, neurovascular unit, brain repair, myeloid cell, microglia, macrophage, neutrophil

INTRODUCTION

The neurovascular unit (NVU) is composed by neurons, endothelial cells, pericytes, smooth muscle cells, astrocytes, microglia and extracellular matrix components. It maintains brain homeostasis of the brain (Banks et al., 2018; Morrison and Filosa, 2019). All the components of NVU interact with each other to maintain the neuronal milieu that is required for proper neuronal functioning by balancing energy, preserving the integrity of the blood brain barrier (BBB), releasing neurotrophic factors, uptake and recycling of neurotransmitters and et al. (Halassa et al., 2007; Charveriat et al., 2017). In response to cerebral ischemic stroke, the integrity of the BBB compromises leading to leakage of harmful blood components into the CNS, immune cell infiltration, and aberrant transport and clearance of molecules. All these changes contribute to the dysfunction of the NVU which is associated with long term neurological impairments (Fisher and Saver, 2015; Villaseñor et al., 2017). The reconstruction of NVU and the remodeling of neuronal circuitry turns out as an essential player in long-term neurological recovery after stroke (Gurer et al., 2009; Lake et al., 2017). However, the repair of NVU is a complex...
process involving clearing of neuronal debris, neurogenesis, angiogenesis, establishing the new neuronal circuitry, controlling neuroinflammation and et al. (Lake et al., 2017; Zh Z. et al., 2017), thus it remains as a big challenge to promote the NVU repair after ischemic brain injury.

After ischemic stroke, both glial cells and peripheral immune cells can be activated by a variety of mechanisms, including neuronal “help me” signals, like lipocalin-2 (Xing et al., 2014; Blochet et al., 2018), interleukin 4 (IL-4) (Zhao et al., 2015), and a complex mixture of extracellular proteins functioning as a damage-associated molecular patterns (DAMPs), such as high-mobility group box 1 (HMGB1), hypoxia-inducible factor 1α (HIF-1α), S100B and et al. (Chamorro et al., 2012; Fu et al., 2015; Li et al., 2018b). Notably, myeloid immune cells are gaining increasing attention due to their unique function in anti-inflammation, clearing cellular debris and promoting neuronal plasticity (Iadecola and Anrather, 2011; Shichita et al., 2014; Fu et al., 2015; Zhao S. C. et al., 2017; Wang X. et al., 2018).

Myeloid cells are blood cells that arise from a large heterogeneous multipotent stem cell population, the hematopoietic stem cells (HSC) lineage (Kondo et al., 1997; Akashi et al., 2000) which resides in the bone marrow and possess the ability to give rise to diverse cell types in the immune system and the blood, including granulocytes, monocytes, erythrocytes and platelets (Paul et al., 2015). Some myeloid populations can develop directly from yolk sac progenitors without apparent bone marrow intermediates, such as tissue resident macrophages (Kondo et al., 1997; Akashi et al., 2000; Shibata and Suzuki, 2017). Although peripheral monocyte-derived macrophages and microglia can both be developed from the same yolk sac progenitors, they should not be considered as one cellular population in the injured brain (Greenhalgh et al., 2018). After injury, monocyte-derived macrophages can enter the brain and directly communicate with microglia and suppress the microglia-mediated phagocytosis and inflammation after spinal cord injury (Greenhalgh et al., 2018). In the central nervous system (CNS), the main tissue resident macrophages including perivascular macrophages (PVM), meningeal macrophages (MM), and choroid plexus macrophages (CPM) (Henning et al., 2009) and microglia migrate into the CNS during early neural development depending on transcription factor Pu.1 and Ifr8 (Hanisch and Kettenmann, 2007; Kierdorf et al., 2013).

In the recent decades, microglia and monocytes/macrophages are intensively studied in the context of cerebral ischemic brain injury (Hu et al., 2012; Garcia-Culebras et al., 2018), with compelling evidence emerging, thus we mainly focused on these cells in this review. After cerebral ischemia, both resident microglia and macrophages can be activated within 24 h and the infiltration of monocyte-derived macrophages and activation of microglia peaks within 3–4 days after stroke onset (Lalancette-Hebert et al., 2007; Gelderblom et al., 2009; Wattananit et al., 2016). Polymorphonuclear neutrophil granulocytes (PMNs) are another myeloid cell population that can infiltrate into the ischemic brain and affect ischemic brain injury (Frijns and Kappelle, 2002). These innate immune cells play important roles in determining the ischemic infarcts. For example, PMNs release matrix metallopeptidase 9 (MMP-9) which degrades the BBB and exacerbates ischemic brain injury (Li et al., 2013a) and tissue-plasminogen activator related hemorrhagic transformation (Mao et al., 2017). Selective microglia elimination disturbed neuronal calcium responses, increased calcium overload and increased the incidence of spreading depolarization, thus significantly increased the infarct size by 60% (Szalay et al., 2016). Depletion of monocyte/macrophages in cerebral ischemic stroke reduced hemorrhagic infarct transformation or reduced brain injury in monocyte/macrophage depleted stroke mice (Gliem et al., 2012; Ma et al., 2016). However, there’s also a recent study showed no impact on stroke outcome with monocyte/macrophages depleted (Schmidt et al., 2017).

Recent researches have highlighted that the impact of these myeloid cells on the ischemic brain injury largely depend on different phenotypes at different stages of stroke (Kurisu et al., 2018). As it’s well-known that microglia and macrophages can be divided into different phenotypes depending on their functions on the inflammatory responses (Mantovani et al., 2013; Guruswamy and ElAli, 2017). Classically-activated (M1) microglia/macrophages usually secret pro-inflammatory cytokines, such as inducible nitric oxide synthase (iNOS), tumor necrosis factor α (TNFα), interleukin 23 (IL-23), interleukin 1β (IL-1β), interleukin 12 (IL-12) and et al. (Mills et al., 2000; Guruswamy and ElAli, 2017; Li et al., 2017), while alternatively activated (M2) microglia/macrophages are characterized by their production of anti-inflammatory cytokines, such as interleukin 10 (IL-10) and transforming growth factor β (TGF-β) (Gordon and Taylor, 2005; Guruswamy and ElAli, 2017) and they can be polarized with IL-4 via a signal transducer and activator of transcription 6 (STAT6)-dependent pathway (Stein et al., 1992; Gao et al., 2015). Recent studies further identified more specific subpopulation of M2 microglia/macrophages, such as M2a, M2b, M2c, and Mox (Hu et al., 2015). Importantly, the phenotypes and functions of these cells are highly dynamic after ischemic injury (Tsuyama et al., 2018). Likewise, PMNs may also have different phenotypes in different stages after ischemic stroke, a pro-inflammatory so called N1 and an anti-inflammatory N2 phenotype (Fridlender et al., 2009).

However, the terminology of microglial/macrophage polarization was questioned and believed to hinder research progress (Ransohoff, 2016). There are far more phenotypes of microglia/macrophages than M1/M2, such as anytotrophic lateral sclerosis specific microglia (Chiu et al., 2013), phagocytic monocyte-derived macrophages (Yamasaki et al., 2014), immunosuppressive CD11c+ microglia and et al. (Kan et al., 2015). There are also cases that microglia/macrophage may concurrently display both pro- and anti-inflammatory phenotypes (Morganti et al., 2016). In addition, transcriptomics and genomic studies reveal that the function of microglia are versatile beyond immune responses, such as synaptic modulation and neurotrophic support (Wes et al., 2016). Single-cell RNA-sequencing gene profiling showed that macrophages in traumatic brain injury are not comprised of distinctly polarized cell subsets, instead, these macrophages are uniquely and broadly activated (Kim et al., 2016). Therefore, it is not rigorous to classify microglia/macrophages imprudently into M1/M2 classifications (Ransohoff, 2016).
Recently, compelling evidence is suggesting the role of the distinct “healing” myeloid cells during the restoration of NVU after stroke, including phagocytosis of damaged neuronal debris, promoting neurogenesis and angiogenesis, re-establishment of the neuronal circuitry, improving white matter repair and et al. during different phases after stroke (Figure 1).

In this review, we will summarize the distinct functions of different subsets of myeloid cells during the “repair” of NVU discuss the identified mechanisms underlying their restoration of the NVU after stroke.

**DIVERGENT FUNCTIONS OF THE “HEALING” MYELOID CELLS DURING NVU REPAIR AFTER ISCHEMIC STROKE**

**Phagocytosis of Damaged Tissue Debris After Stroke**

By removing necrotic tissues, myeloid cells may accelerate brain repair by enhanced phagocytosis after intracerebral hemorrhage (ICH) (Wan et al., 2016; Fumagalli et al., 2019). Using structured illumination microscopy, a super-resolution technique which helps study phagocytosis, it was shown that myeloid cells were encompassed with potent phagocytic abilities once they infiltrated into the ischemic brain (Fumagalli et al., 2019). There are several different receptors expressed on microglia/macrophages that mediate the phagocytosis of these cells, including class A, class B scavenger receptors, the surface receptor triggering receptor expressed on myeloid cells-2 (TREM2), complement receptors (CRs) (Dustin, 2016), mannose receptors (Galea et al., 2005) and the mer receptor tyrosine kinase (MerTK) (Healy et al., 2016, 2017). In addition, purinergic receptors, such as P2Y12 receptors as key regulators of microglia process extension, also contribute to their responses to brain injury (Kluge et al., 2017; Fukumoto et al., 2018). We will briefly summarize the phagocytic aspects of some recently studied receptors after stroke (Figure 2).

**The Class A Scavenger Receptors**

The class A scavenger receptor includes macrophage scavenger receptor 1(Msr1) and macrophage receptor with collagenous structure (Marco). Msr1 is also known as CD204. Both of these receptors are important for the clearance of DAMPs, including peroxiredoxins, high mobility group box 1 protein and S100 calcium-binding protein A8/9 from the ischemic brain (Mîne et al., 2005; Shichita et al., 2017). Msr1 is up-regulated in infiltrating mononuclear phagocytes from day 1 to day 3 after stroke onset and is dependent on the transcription factor Mafb, which plays an important role in the regulation of lineage-specific hematopoiesis (Shichita et al., 2017). Combined Msr1 and Marco deficiency results in sustained inflammation, leading to impaired clearance of DAMPs and ultimately an enlarged infarct volume and exacerbated neurological deficits (Shichita et al., 2017). The expression level of Msr1 helps to distinguish the repairing macrophages from inflammatory ones, since Msr1 hi macrophages express less inflammatory cytokines (TNF-α, IL-1β, and IL-23) and are instead the major sources of insulin-like growth factor-1 (IGF-1), a neurotrophic factor (Shichita et al., 2017).

**FIGURE 1** | The involvement of myeloid immune cells during the NVU repair after cerebral ischemic stroke. In the acute phase of ischemic stroke, the damaged associated signals from the ischemic brain activate resident and peripheral myeloid immune cells, such as microglia, peripheral mono/macrophages and neutrophils. These cells penetrate into the CNS through the disrupted BBB from 1 day after stroke, peaking at 2–3 days and may last for several weeks. The phagocytic function of myeloid cells enables them to remove tissue debris in both acute and repair stages. During the recovery phase after stroke, myeloid cells with strong plasticity could differentiate into different phenotypes and release several neurovascular nutritional factors, which may enhance neurovascular regeneration and remodeling up to weeks and months after stroke. NVU, neurovascular unit; CNS, central nervous system; BBB, blood brain barrier; NSC, neural stem cells.
FIGURE 2 | The receptors that mediate phagocytosis of myeloid immune cells. Several receptors have been suggested to mediate the phagocytosis of myeloid cells, such as the class A scavenger receptor Marco and Msr1, the class B scavenger receptor CD36, TREM2, CRs, MRs, and MerTK. Myeloid cells can phagocytose the DAMPs released from damaged neurons with the receptors such as Msr1 and Marco, which subsequently downregulate the neurovascular inflammation and enhance brain repair. Through CD36, myeloid cells can also clear tissue debris from apoptotic cells, thrombospondins, oxidized lipid, et al. TREM2 is important for preventing microglia apoptosis, it also promotes the survival of microglia via the Wnt/β catenin pathway. Complement receptor, such as CR1 and CR3, may bind to apoptotic neuronal cells and contribute to clearing debris and limiting neuroinflammation. MerTK is associated with the myeloid phagocytosis of myelin, neurons and eryptotic erythrocytes, leading to prevent delayed neuronal loss after stroke. CD36, cluster of differentiation 36; TREM2, triggering receptor expressed on myeloid cells 2; CRs, complement receptors; MRs, mannose receptors; MerTK, the mer receptor tyrosine kinase; DAMP, danger associated molecular pattern; Msr1, macrophage scavenger receptor 1; Marco, macrophage receptor with collagenous structure.

The Class B Scavenger Receptor Cluster of Differentiation 36 (CD36)
The class B scavenger receptor CD36, is a highly glycosylated integral membrane protein expressed in microglia and monocytes/macrophages (Cho et al., 2005; Woo et al., 2016). With high affinity toward apoptotic cells and many ligands such as thrombospondins (TSPs), fibrillary amyloid β and oxidized lipids, CD36 has been suggested to play a pivotal role in the clearance of cell debris during the recovery phase in post-stroke brains (Cho et al., 2005; Woo et al., 2016; Stamova et al., 2018). Stroke induces increased mRNA expression of CD36 and TSP-1/2 mRNA levels in the ipsilateral hemisphere both during the acute and recovery phases (Woo et al., 2016). Deletion of CD36 results in poorer outcome due to lack of attenuation of nuclear factor-κB (NF-κB) mediated inflammation and diminished removal of apoptotic neuronal debris (Woo et al., 2012). CD36 deficiency or SS-31, a cell permeable tetra-peptide known to down-regulate CD36 pathway, significantly attenuated monocyte chemoattractant protein 1 (MCP-1), C-C chemokine receptor type 2 (CCR2) mRNA up-regulation and injury size in the transient ischemic stroke (Kim et al., 2015). Increased expression of CD36 expression in monocyte/macrophages has been associated with higher phagocytic indices in the brain immune cells after ischemic stroke (Woo et al., 2016).

The Surface Receptor TREM2
The surface receptor TREM2 is expressed exclusively on myeloid cells, including brain microglia (Hakola, 1972; Nasu et al., 1973). It was first identified as a genetic cause of neurodegenerative disease called Nasu-Hakola disease [or polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL)] (Hakola, 1972; Nasu et al., 1973). It is characterized as axonal degeneration and white matter loss, as well as cortical atrophy in clinical patients (Sasaki et al., 2015). TREM2 binds anionic carbohydrates, anionic bacterial products and various phospholipids (Daws et al., 2003; Cannon et al., 2012). It transmits intracellular signals through the associated transmembrane adapter DNA activation protein of 12 kDa (DAP12), an immune-receptor tyrosine-based activation motif (ITAM)-bearing adapter molecule that transduces activating signals in natural killer (NK) and myeloid cells (Peng et al., 2010). DAP 12 can recruit the protein tyrosine kinase Syk, which phosphorates phosphoinositide phospholipase C-γ (PLC-γ), phosphoinositide 3-kinases (PI3Ks) and Vav2/3 to induce the mobilization of intracellular calcium and the reorganization of actin and prevent apoptosis (Peng et al., 2010). TREM2 also stabilizes β-catenin by inhibiting its degradation via the Akt/GSK3β signaling pathway, thus promotes microglial survival (Zheng et al., 2017). TREM2 expression has been associated...
with phagocytic activities of microglia in cerebral ischemia and Alzheimer’s disease (AD) (Kawabori et al., 2015; Wu et al., 2017; Kurisu et al., 2018; Wei et al., 2019). Loss of TREM2 results in reduced phagocytosis of a variety of substrates, including apoptotic neurons (Hsieh et al., 2009), amyloid plaques and anionic and zwitterionic lipids on damaged neurons (Wang et al., 2015; Yuan et al., 2016). Using bone marrow chimeric mice, it has been shown that TREM2 on the brain microglia is more essential to post-stroke recovery compared to those on circulating macrophages (Kurisu et al., 2018).

CRs in Myeloid Cells
The complement system is emerging as an important player of cerebral ischemic brain injury. A variety of complement proteins have been shown to be induced after cerebral ischemic stroke, such as C1q, C3a and C3b (Fumagalli et al., 2019). It has been shown that C1q can bind to apoptotic neuronal cells and produce opsonizing C3b and C4b fragments, which are responsible for phagocytosis of apoptotic cells. Furthermore, C1q also binds to IgM, pentraxin-3 and serum amyloid P component during the C1q-mediated removal of apoptotic cells. C1q<sup>−/−</sup> mice exhibited impaired elimination of immune complexes and were more susceptible to neuroinflammation (Orsini et al., 2014). There are several CRs that have been linked to the phagocytic function of myeloid cells, such as CR1 and CR3 (Dustin, 2016). CR1 is a membrane-bound glycoprotein and is a receptor for C3b and C4b. It has been shown that the expression of CR1 on microglia was increased after lipopolysaccharide (LPS) induction and played a detrimental role in neuronal death after LPS stimulation or in the pathology of AD. However, the role of CR1 in the context of ischemic stroke remains unknown. CR3, also known as CD11b/CD18 or Mac-1 (Ma et al., 2019) is a member of the integrin β2 subfamily. It is deeply involved in the innate immune responses and also the induction of phagocytosis by interacting with its ligand iC3b. The phagocytosis mediated by C3b is usually beneficial for clearing debris, apoptotic or necrotic neurons and limiting neuroinflammation after brain injury (Rotshenker, 2003; Fourgeaud and Boulanger, 2007).

Mannose Receptors (MRs)
The MRs, also known as cluster of differentiation 206, CD206, are C-type lectin which can express on microglia/macrophages, dendritic cells and et al. The extracellular region of MRs include an N-terminal cysteine-rich domain that is able to bind sugars with high affinity, such as mannose and fructose, thus scavenging unwanted high mannose N-linked glycoproteins from the circulation (Lee et al., 2002). The expression of MRs has been shown to increase after cerebral ischemic stroke in the phagocytic microglia/macrophages within the ischemic boundary (Giraldi-Guimaraes et al., 2012). Induction of increased MRs expression is believed to enhance the clearance ability of microglia/macrophages and thus provide neuroprotection against ischemic stroke (Giraldi-Guimaraes et al., 2012).

Tyrosine Kinase Receptor, MerTK
MerTK is a member of tyrosine kinase receptor family that plays important role in mediating phagocytosis by myeloid cells. The expression of MerTK is correlated with the myelin phagocytosis of myeloid cells not only in multiple sclerosis (Healy et al., 2016, 2017), but also the phagocytosis of ischemic neurons after cerebral ischemia (Neher et al., 2013). After ischemic stroke, the expression MerTK was transiently upregulated. Inhibition of MerTK may prevent delayed neuronal loss after stroke (Neher et al., 2013). In the model of ICH, loss of MerTK reduced hematoma clearance and exacerbated iron deposition, thus worsened neurological recovery (Chang et al., 2018). Therefore, MerTK is a receptor that is associated the phagocytosis of a variety targets, such as myelin, neurons and erythrocytes.

Collectively, there are multiple phagocytic receptors expressed on myeloid cells that are promising in clearing the debris and promoting brain repair after stroke. However, the roles and the underlying mechanisms of some phagocytic receptors remain largely unknown in the context of cerebral ischemia and thus warrant further investigation.

**Anti-inflammatory Effect of Myeloid Cells and Brain Repair After Stroke**
Mounting studies have suggested that the alternatively activated or anti-inflammatory phenotype of microglia/macrophages are characterized in their anti-inflammatory effects, with the signature proteins expressed, such as arginase-1, CD206 or macrophage MR, Ym1 and TGFβ and IL-10 (Gordon and Taylor, 2005; Hu et al., 2015; Miro-Mur et al., 2016; Ge et al., 2017; Gaceb et al., 2018). Several mechanisms have been suggested to induce the anti-inflammatory effect of microglia and macrophages, such as the activation of chemokine (C-X3-C motif) ligand 1-CX3C chemokine receptor 1 (CX3CL1-CX3CR1) signaling, IL-33/ST2 signaling and IL-4/peroxisome proliferator-activated receptor γ (PPARγ) signaling (Mizuno et al., 2003; Lyons et al., 2009; Liu X. et al., 2016; Yang et al., 2017). High expression of endogenous CX3CL1 in neurons acts as an “on” signal to stop the quiescent state of microglia and leads to a tonic activation of CX3CR1 on microglia and acts as a neuronal “off” signal maintaining microglia in a quiescent state (Biber et al., 2007; Eyo and Wu, 2013). CX3CR1<sup>+</sup>Ly6C<sub>low</sub> “patrolling” monocytes may play a role in repair processes in the ischemic brain (Garcia-Bonilla et al., 2016). However, there are also studies showing that Ly6C<sub>hi</sub> monocytes are protective in acute ischemic stroke by promoting macrophage polarization (Chu et al., 2015). IL-4 was able to induce peroxisome proliferator-activated receptor γ (PPARγ) activation thereby enhanced long-term functional recovery of cerebral ischemic stroke (Zhao et al., 2015). ST2, a member of the IL-1 receptor family, and its ligand interleukin-33-33(IL-33) play critical roles in immune regulation and inflammatory responses. ST2 deficiency aggravates neurological deficits up to 7 d after transient middle cerebral artery occlusion (Yang et al., 2017). The IL-33/ST2 signaling potentiates the expression of IL-10 and other anti-inflammatory genes in primary microglia and stimulates the production of IL-10 from microglia, which, in turn, enhances neuronal survival after ischemic insult (Yang et al., 2017). Recent evidence suggests that similar to the concept of classically activated and alternatively activated macrophages, neutrophils also have pro-inflammatory and anti-inflammatory phenotypes, called N1 and N2 phenotypes.
Promoting Neurogenesis and Angiogenesis

**Neurogenesis**

Neurogenesis is a key step toward recovery from cerebral ischemic stroke (Sun et al., 2018). It is a natural process that occurs in the adult hippocampus everyday as was shown by a previous study measuring the concentration of nuclear-bomb-test-derived 14C in genomic DNA (Spalding et al., 2013). After stroke, neurogenesis can be induced in the ipsilateral subventricular zone (SVZ) 1 to 2 weeks after the ischemic insult and cell proliferation returns to baseline 6 weeks later (Thored et al., 2006). In addition, stroke also induces neuroblasts to differentiate into neurons (Arvidsson et al., 2002) or to elicit a neurogenic program in striatal astrocytes in mice (Magnusson et al., 2014).

Microglia possess the ability to support neurogenesis after ischemic stroke through pleiotropic mechanisms (Ziv et al., 2006; Kettenmann et al., 2011). During 2, 6 and 16 weeks after middle cerebral artery occlusion, there are more activated microglia migrating from the ipsilateral SVZ to the striatum together with neuroblasts in rats (Thored et al., 2009). These microglia exhibit pro-neurogenic phenotypes with increased expression of IGF-I, which can promote proliferation and differentiation of neural stem cells (NSCs) (Thored et al., 2009) and contribute to neural repair and survival after ischemic injury (Zhu et al., 2009). Removal of proliferating microglia by ganciclovir treatment decreases the level of neurotrophic IGF1, leading to the exacerbation of ischemic neuronal damage and deteriorated stroke outcomes (Lalancette-Hebert et al., 2007). Therefore, microglia are believed to have a predominantly repairing function in promoting the survival of neurons in the resolution phase of ischemic brain injury (Szalay et al., 2016).

Brain-derived neurotrophic factor (BDNF) is another important neurotropic protein that can be produced by microglia after stroke (Cook et al., 2017; Verma et al., 2017). It has been shown to regulate synaptic function and promote multiple learning tasks performance (Coull et al., 2005; Parkhurst et al., 2013). The micro-environment of microglia/macrophage is critical for their pro-neurogenic properties. Microglia activated by IL-4 and interferon γ (IFNγ) promote neurogenesis, while LPS activated microglia block neurogenesis in hippocampal slice cultures (Butovsky et al., 2005; Liu et al., 2013). Modulation of the polarization of microglia/macrophages with chronic metformin treatment is associated with enhanced angiogenesis and neurogenesis after cerebral ischemic stroke (Jin et al., 2014). Meningeal macrophage polarization induced by BCG vaccination is helpful for the neurogenesis and spatial cognition (Qi et al., 2017). In the neuron-macrophage co-culture, it has been shown that molecular factors secreted by macrophages can promote neurite outgrowth (Yun et al., 2018).

**Angiogenesis and Vascular Remodeling**

Remodeling of the cerebral vasculature after cerebral ischemic stroke involves angiogenesis and also the growth of new blood vessels from pre-existing vascular tree, both of which ultimately promotes the re-establishment of the microcirculation and the blood supply to the damaged brain tissue (Lapi and Colantuoni, 2015). Vascular remodeling can last for more than 3 weeks after cerebral ischemia. It has been associated with improved neurological outcome after stroke (Lapi and Colantuoni, 2015). Vascular endothelial growth factor (VEGF) and endothelium-released nitric oxide are important factors in the generation of new vessels and formation of new vasculature during microvascular remodeling (Lapi and Colantuoni, 2015). Monocytes/macrophages can express interleukin-8 (IL-8), VEGF, TGF-β, prostaglandin, and MMP-9, all of which can enhance the angiogenic process after stroke (Sanberg et al., 2010). In addition to secreting angiogenic factors, macrophages can also repair the ruptured vascular mechanically (Liu C. et al., 2016). Using in vivo time-lapse imaging in zebrafish, it has been shown that macrophage arrive at the cerebral vascular rupture lesion and extend their filopodia or lamellipodia to physically adhere to both endothelial ends (Liu C. et al., 2016). Furthermore, these macrophages can promote the ligation and the repair of the rupture by generating mechanical traction forces to pull the endothelial ends (Liu C. et al., 2016; Figure 3).

**Re-establishment of the Neuronal Circuit by Enhancing Axonal Sprouting and Synaptic Plasticity**

To achieve functional recovery after stroke, the newly generated or differentiated neurons need reorganization and rewiring in the ischemic lesion. These remodeling processes are often...
FIGURE 3 | The roles of myeloid cells for neurovascular remodeling. Microglia switch into pro-neurogenic phenotype and anti-inflammatory phenotype with increased release of IGF-1, BDNF and anti-inflammatory cytokines, which promote the proliferation and differentiation of NSCs, leading to enhanced neurogenesis, neural repair and NSC survival and differentiation. Furthermore, myeloid cells express angiogenic factors as IL-8, VEGF et al to promote vascular repair. Moreover, they could generate mechanical traction forces to pull the injured endothelial ends, rebuilding the ligation to enhance repair. IGF, insulin-like growth factor; BDNF, brain derived neurotrophic factor; NSC, neural stem cells; IL-8, interleukin 8; VEGF, vascular endothelial growth factor.

associated with the sprouting of spared axons and modifying the synaptic networks to establish new circuits (Chu et al., 2015). Interestingly, emerging evidence is suggesting that microglia can rapidly modify neuronal activity, modulate synaptic function and promote the integration of NPCs from endogenous neurogenic niches into functional networks after brain injury (Wake et al., 2013; Sandvig et al., 2018). In addition, recent evidence suggests that microglia/macrophages play an important role in the remyelination through protecting oligodendrocytes, augmenting oligodendrogenesis and promoting oligodendrocyte progenitor cell (OPC) differentiation both in stroke and other neurodegenerative diseases (Miron et al., 2013; Moore et al., 2015; Hagemeyer et al., 2017). By regulating the phenotypic switch of microglia with IL-4 or inducing iron-releasing phenotype with noggin, a bone morphogenetic protein (BMP) antagonist, the “healing” capacity toward remyelination of microglia can be significantly enhanced (Shin et al., 2018). Administration of iron-sulfur glutaredoxin 2, the oxidoreductase, inhibits peroxynitrite formation thus reduces the nitric oxide release from activated microglia and protects oligodendrocytes from myelin damage in experimental autoimmune encephalomyelitis (Lepka et al., 2017). Activation of microglia with IL-13 or IL-10 not only induces generation of OPCs from the SVZ after focal demyelination in the corpus callosum (Naruse et al., 2018), but also enhances the survival and differentiation of these cells during CNS remyelination (Miron et al., 2013; Figure 4).

POTENTIAL THERAPEUTIC STRATEGIES
TARGETING MYELOID CELLS IN THE TREATMENT OF ISCHEMIC STROKE

Bone Marrow Derived Stem Mononuclear Cells Transplantation
Bone-marrow derived mononuclear cells (MNCs) based therapy is gaining increasing attention because of the pleotropic effects in improving neurological recovery after stroke (Brenneman et al., 2010; Vahidy et al., 2016; Yang et al., 2012). Interestingly, with increased expression of IL-10, IL-6, MCP-1, VEGF, and TNF-α, post-stroke MNCs treatment leads to a better recovery on neurological testing and reduces lesion size as compared to pre-stroke MNCs (Yang et al., 2012). In 2016, thirty-nine patients with subacute ischemic cerebral infarct due to large artery occlusion in the middle cerebral artery (MCA) territory were recruited to receive bone marrow mononuclear (BMMN) stem cell transplantation. The study suggests that it is safe to transplant autologous BMMN stem cell intra-arterially in subacute MCA ischemic stroke patients, but unfortunately, no significant improvement of motor, language disturbance, or infarction volume was detected in the stem cell-treated group as compared to the non-treated group within an observation period of 12 months (Deierborg et al., 2010).
Adoptive Transfer of Monocytes/Macrophages

It’s recently proposed that preconditioned monocytes/macrophages may play an endogenous protective role after ischemic brain injury (Garcia-Bonilla et al., 2018). Depletion of circulating monocytes/macrophages or selective targeting of CCR2 in bone marrow-derived cells exacerbated the BBB disruption and thus caused delayed clinical deterioration and hemorrhagic conversion of the infarctions after stroke (Gliem et al., 2012). On the other hand, transfer of splenic monocytes isolated from preconditioned mice into naive mice 7 h after transient MCAO reduced ischemic brain injury (Garcia-Bonilla et al., 2018). Mechanistically, gene expression and functional studies showed that IL-10, inducible nitric oxide synthase, and CCR2 in monocytes are essential for the neuroprotection (Garcia-Bonilla et al., 2018). Interestingly, a clinical study with 13 stroke patients and 13 case-control stroke patients showed that intrathecal injection of autologous M2 macrophages in stroke patients is safe and may lead to improved neurological recovery (Chernykh et al., 2016). Although the study is still preliminary with a small sample size, it opens up a new direction toward myeloid-cell based stroke therapy to protect the ischemic brain.

Nevertheless, when it comes to immune-cell based therapy, it’s always important to consider the condition of the recipients. For example, in our previous study, we found adoptive transfer of regulatory T cells or in vivo expansion of regulatory T cells could protect against cerebral ischemic injury (Li et al., 2013b; Zhang et al., 2018) and meanwhile preserve the immune homeostasis after stroke (Li et al., 2013b). However, the immune suppressive regulatory T cells may be attracted to the tumor via the VEGF-neuropilin 1 signaling when the stroke recipient is complicated by cancer (Wang L. et al., 2018). Other critical issues related to immune cell-based therapy include availability or preparation of immune cells, major histocompatibility complex molecules which may initiate immune responses, preservation of purified immune cells and et al., all of which hinder the clinical translation of immune cell-based therapies.

Mitochondrial Dynamic of Myeloid Cells as Therapeutic Target

Mitochondria, a highly dynamic cellular organelle that plays pivotal role in metabolism and apoptosis is also deeply involved in the interplay between cellular metabolism and both innate and adaptive immune responses (Tur et al., 2017). They govern the dependence of cellular metabolism and the coordination of the tricarboxylic acid (TCA) cycle to modulate oxidative phosphorylation rates and adenosine triphosphate (ATP) production, as well as the important intermediates to support other metabolic processes (Tur et al., 2017). Therapeutically restoring mitochondrial function can reprogram inflammatory macrophages into anti-inflammatory cells by regulating cellular metabolic pathways (Van den Bossche et al., 2016). Alternatively activated or naïve macrophages predominantly use oxidative phosphorylation for their energy support, whereas the aerobic glycolysis and pentose phosphate pathway can be robustly enhanced in classically activated macrophages (Liu and Ho, 2018), with significantly increased
glucose uptake. Whereas the fatty acids uptake is enhanced to support anti-inflammatory microglia/macrophage polarization and functions (Van den Bossche et al., 2016). As the central regulator of cellular metabolism, mitochondria are emerging as a pivotal therapeutic target to regulate the phenotype polarization of microglia/macrophages (Mehta et al., 2017). After cerebral ischemic stroke, enhanced glycolysis and fatty acid synthesis have been found in peripheral T cells, with increased expression of acetyl-coenzyme A (Wang et al., 2019). Hyper-glycolysis can induce the key glycolytic enzyme hexokinase 2 (HK2), which further results in accumulated acetyl-coenzyme A and subsequent histone acetylation and transcriptional activation of interleukin (IL)-1β and over-activation of the microglia-mediated neuroinflammation after cerebral ischemic stroke (Li et al., 2018a). However, it still should be kept in mind that the phenotypes of microglia/macrophages are far more complicated than pro-inflammatory or anti-inflammatory as we mentioned above. How does the mitochondria function and the metabolic process affect other phenotypes still remains largely unknown.

### Immunological Effects of Extracellular Vesicles (EVs) on Ischemic Stroke

Extracellular vesicles (EVs) which can be released by almost all cell types can appear in all body fluids as membrane-surrounded vesicles. There are two distinct types of EV according to their origin: shedding microvesicles apoptotic bodies and exosomes. Because exosomes are able to cross the BBB and the blood-cerebrospinal fluid barrier, it allows crosstalk between the periphery and the brain. On one hand, damaged endothelium releases pro-inflammatory factors and EVs that pass through the compromised BBB after stroke. These EVs can activate microglia and astrocytes to release pro-inflammatory cytokines (TNFα, IL1β) (Zagrean et al., 2018). On the other hand, exosomes are emerging as a powerful diagnostic tool and a promising therapeutic shuttle of natural nanoparticles (Zagrean et al., 2018). It has been suggested that microglia-derived exosomes may contain microRNAs (miR-124-3p) that can inhibit neuronal inflammation and promote neurite outgrowth by transferring into neurons after traumatic brain injury (Ponomarev et al., 2013; Huang et al., 2018).

### TABLE 1 | Potential immunotherapeutic targets on myeloid cells for NVU repair after stroke.

| Cellular targets | Functions and underlying mechanisms | References |
|------------------|-------------------------------------|------------|
| Msr1             | Clearance of DAMPs; reduce the expression of inflammatory cytokines | Shichita et al., 2017 |
| CD36             | Clearance of cell debris; attenuation of nuclear factor-κB mediated inflammation; | Cho et al., 2005; Woo et al., 2012 |
| TREM2            | Promotes microglial survival by inhibiting β-catenin degradation via the Akt/GSK3β signaling pathway; phagocytosis apoptotic neurons, amyloid plaques and anion and zwitterionic lipids on damaged neurons | Hsieh et al., 2009; Wang et al., 2015; Yuan et al., 2016; Zheng et al., 2017 |
| CR1              | Induction of phagocytosis by interacting with its ligands; clearing debris, apoptotic or necrotic neurons and limiting neuroinflammation | Rotshenker, 2003; Fourgeaud and Boulanger, 2007 |
| MRs              | Enhance the clearance ability of microglia/macrophages | Giraldi-Guimaraes et al., 2012 |
| MerTK            | Phagocytosis of ischemic neurons; clearance of hematoma and reduce iron deposition | Neher et al., 2013; Chiang et al., 2018 |
| arginase-1, CD206, Ym1 and TGFβ and IL-10 | Induce the anti-inflammatory effect of microglia and macrophages by activating CX3CL1-CX3CR1 signaling, IL-33/ST2 signaling and neuronal IL-4, PPARγ | Mizuno et al., 2003; Lyons et al., 2009; Zhao et al., 2015; Liu X. et al., 2016; Yang et al., 2017 |
| PPARγ in N2 neutrophils | Limit excessive immune response, promoting neuronal survival and successful brain remodeling after ischemic stroke and ICH | Hermann et al., 2018 |
| lactoferrin      | Iron-scavenging and clearance of hematoma | Zhao X. et al., 2017 |
| IGF-1            | Promote proliferation and differentiation of NSCs | Thored et al., 2009 |
| BDNF             | Regulate synaptic function and promote multiple learning tasks performance | Coull et al., 2005 |
| IL-8, VEGF, TGF-β, prostaglandin, MMP-9 | Enhance the angiogenic process | Sanberg et al., 2010 |
| Filopodia or lamellipodia | Physically adhere to both endothelial ends at the cerebral vascular rupture lesion | Liu C. et al., 2016 |
| iron-releasing phenotype of microglia | Promoting oligodendrocyte progenitor cell differentiation | Shin et al., 2018 |
| EVs, exosomes, miRNA124-3p | Inhibit neuronal inflammation and promote neurite outgrowth | Ponomarev et al., 2013; Huang et al., 2018 |

NVU, neurovascular unit; Msr1, macrophage scavenger receptor 1; DAMP, damage associated molecular patterns; CD36, cluster of differentiation 36; TREM2, triggering receptor expressed on myeloid cells-2; CR, complement receptor; MR, mannose receptor; MerTK, mer receptor tyrosine kinase; PPARγ, peroxisome proliferator-activated receptor γ; CX3CL1-CX3CR1, chemokine (C-X3-C motif) ligand 1-CX3C chemokine receptor 1; IL-33, interleukin 33; IL-4, interleukin 4; ICH, intracerebral hemorrhage; IGF-1, insulin-like growth factor-1; NSC, neural stem cell; BDNF, brain-derived neurotrophic factor; IL-8, interleukin 8; VEGF, vascular endothelial growth factor; TGF-β, transforming growth factor β; MMP-9, matrix metallopeptidase 9; EVs, extracellular vesicles.
In addition, intravenous administration of macrophage exosomes can cross the BBB which serve as natural nanocarriers to deliver a cargo protein, the brain derived neurotrophic factor to the injured brain (Yuan et al., 2017). Treatment with exosomes secreted from LPS-stimulated macrophage or MNCs has been shown to reduce brain infarct volume and improve neurological function after focal cerebral ischemic stroke (Altmann et al., 2014; Zheng et al., 2019). In addition, exosomes derived from several different cell types, such as mesenchymal stromal cells, adipose-derived stem cells (ADSCs), embryonic stem cells (ESG) and neural stem cells (NSG) (Rufino-Ramos et al., 2017; Cunningham et al., 2018; Webb et al., 2018), and exosomes from these cells have been shown to reduce ischemic volume, promote white matter repair and help neurovascular restoration following ischemia-reperfusion injury (Xin et al., 2013; Otero-Ortega et al., 2017; Jiang et al., 2018; Venkat et al., 2018; Webb et al., 2018). Therefore, it’s reasonable to envision that the exosome from the “healing” type of myeloid cells holds the promise to serve as an intriguing therapeutic strategy for future stroke therapy.

CONCLUDING REMARKS AND FUTURE PERSPECTIVES

As highlighted in this review, myeloid cells play an important role in tissue remodeling during the late stage of stroke via pleiotropic mechanisms, such as inhibiting immune inflammation, devouring harmful factors, removing tissue fragments, secreting neurotrophic substances, et al. Scavenger receptors such as Msf1, CD36, TREM2, CRs, MRs and MerTK all contribute to the clearing of necrotic debris and set the stage for NVU remodeling in the repair phase. Several mechanisms are involved in their anti-inflammatory functions to turn into potential protective phenotype through secreting anti-inflammatory cytokines such as IL-10 and TGF-β. With their “healing” effects during neurovascular renewal, myeloid cells are promising to provide novel therapeutic targets (Table 1). Meanwhile, myeloid cell-based therapy, such as bone marrow derived myeloid stem cell perfusion, mitochondrial therapy and EVs-based therapy are also gaining increasing attention for the stroke treatment. However, there are myriad unknown areas that warrant further investigation to foster novel therapeutic strategies, such as the complex mix of "help me” signals that initiate the activation and functional switching of myeloid cells, the interactions between the NVU repair processes and myeloid cells and the underlying mechanisms. As our understanding of the role of myeloid cells in the post-stroke NVU repair grows, we may have the potential to design better myeloid cell targeted treatments to improve the neurological outcome of stroke patients.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

PL is supported by the National Natural Science Foundation of China (NSFC) grant 81722017 and the Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support (20181805). WY is supported by the National Natural Science Foundation of China (81571048). YC is supported by the National Natural Science Foundation of China (NSFC) grant 81801095.

REFERENCES

Akashi, K., Traver, D., Miyamoto, T., and Weissman, I. L. (2000). A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193–197. doi: 10.1038/35004599

Altmann, P., Mildner, M., Haider, T., Traxler, D., Beer, L., Ristl, R., et al. (2014). Secretomes of apoptotic mononuclear cells ameliorate neurological damage in rats with focal ischemia. F1000Res 3:131. doi: 10.12688/f1000research.4219.2

Arvidsson, A., Collin, T., Kirik, D., Kokaia, Z., and Lindvall, O. (2002). Neuronal replacement from endogenous progenitors in the adult brain after stroke. Nat. Med. 8, 963–970. doi: 10.1038/nm477

Banks, W. A., Kovac, A., and Morofuji, Y. (2018). Neurovascular unit crosstalk: pericytes and astrocytes modify cytokine secretion patterns of brain endothelial cells. J. Cereb. Blood Flow Metab. 38, 1104–1118. doi: 10.1177/0271678x17740793

Biber, K., Neumann, H., Inoue, K., and Boddeke, H. W. (2007). Neuronal 'On' and 'Off' signals control microglia. Trends Neurosci. 30, 596–602. doi: 10.1016/j.tins.2007.08.007

Blochet, C., Buscemi, L., Clément, T., Gehri, S., Badaut, J., and Hirt, L. (2018). Involvement of caveolin-1 in neurovascular unit remodeling after stroke: effects on neurovascularization and astroglisisis. J. Cereb. Blood Flow Metab. doi: 10.1177/0271678x18806893 [Epub ahead of print]

Brenneman, M., Sharma, S., Harting, M., Strong, R., Cox, C. S. Jr., Aronowski, J., et al. (2010). Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats. J. Cereb. Blood Flow Metab. 30, 140–149. doi: 10.1038/jcbfm.2009.198

Butovsky, O., Talpalar, A. E., Ben-Yaakov, K., and Schwartz, M. (2005). Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol. Cell. Neurosci. 29, 381–393. doi: 10.1016/j.mcn.2005.03.005

Cannon, J. P., O’driscoll, M., and Litman, G. W. (2012). Specific lipid recognition is a general feature of CD30 and TREM molecules. Immunogenetics 64, 39–47. doi: 10.1007/s00251-011-0562-4

Chamorro, A., Meisel, A., Planas, A. M., Urra, X., Van De Beek, D., and Veltkamp, R. (2012). The immunology of acute stroke. Nat. Rev. Neurol. 8, 401–410. doi: 10.1038/nrneurol.2012.98

Chang, C. F., Goods, B. A., Askenas, M. H., Hammond, M. D., Renfroe, S. C., Steinschneider, A. F., et al. (2018). Erythrocyte efferocytosis modulates macrophages towards recovery after intracerebral hemorrhage. J. Clin. Invest. 128, 607–624. doi: 10.1172/JCI95612

Charveriat, M., Naus, C. C., Leybaert, L., Saez, J. C., and Giaume, C. (2017). Connexin-dependent neuroglial networking as a new therapeutic target. Front. Cell. Neurosci. 11:74. doi: 10.3389/fncel.2017.00714

Chernykh, E. R., Shevela, E. Y., Starostina, N. M., Morozov, S. A., Davydova, M. N., Menyaeva, E. V., et al. (2016). Safety and therapeutic potential of M2 macrophages in stroke treatment. Cell Transplant. 25, 1461–1471. doi: 10.3727/096368915X690279
Chiu, I. M., Morimoto, E. T., Goodarzi, H., Liao, J. T., O'keefe, S., Phatnani, H. P., et al. (2013). A neurodegeneration-specific gene expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 4, 385–401. doi: 10.1016/j.celrep.2013.06.018

Cho, S., Park, E. M., Febrero, M., Anrather, J., Park, L., Racchumi, G., et al. (2005). The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J. Neurosci. 25, 2504–2512. doi: 10.1523/jneurosci.0035-05-2005

Chu, H. X., Broughton, B. R., Kim, H. A., Lee, S., Drummond, G. R., and Sobey, C. G. (2015). Evidence that Ly6C(hi) monocytes are protective in acute ischemic stroke by promoting M2 macrophage polarization. Stroke 46, 1929–1937. doi: 10.1161/strokeaha.115.009426

Cook, D. J., Nguyen, C., Chun, H. N., Llorente, I. L., Chu, A. S., Machnicki, D., et al. (2015). Hydrogel-delivered brain-derived neurotrophic factor promotes tissue repair and recovery after stroke. J. Cereb. Blood Flow Metab. 37, 1030–1045. doi: 10.1038/jcbfm.2016.499

Coull, J. A., Beggs, S., Broudeur, D., Boivin, D., Tsauda, M., Inoue, K., et al. (2005). BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438, 1017–1021. doi: 10.1038/nature4223

Cuartemo, M. I., Ballesteros, L., Moraga, A., Nombela, F., Vivancos, J., Hamilton, J. A., et al. (2013). N2 neutrophils, novel players in brain inflammation after stroke: modulation by the PPARGamma agonist rosiglitazone. Stroke 44, 3498–3508. doi: 10.1161/strokeaha.113.002470

Cunningham, C. J., Redondo-Castro, E., and Allan, S. M. (2018). The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke. J. Cereb. Blood Flow Metab. 38, 1276–1292. doi: 10.1038/s41600-017-0060-2

Daws, M. R., Sullan, P. M., Niemi, E. C., Chen, T. T., Tchao, N. K., and Seaman, W. E. (2003). Pattern recognition by TREM-2: binding of anionic ligands. J. Immunol. 171, 594–599. doi: 10.4049/jimmunol.171.2.594

Deierborg, T., Roybon, L., Inacio, A. R., Pesic, J., and Brundin, P. (2010). Brain injury activates microglia that induce neural stem cell proliferation ex vivo and promote differentiation of neurosphere-derived cells into neurons and oligodendrocytes. Neuroscience 171, 1386–1396. doi: 10.1016/j.neuroscience.2010.09.045

Dustin, M. L. (2016). Complement receptors in myeloid cell adhesion and phagocytosis. Microbiol. Spectr. 4, doi: 10.1128/microbiolspec.MCHD-0034-2016

Eyo, U. B., and Wu, L. J. (2013). Bidirectional microglia-neuron communication in the healthy brain. Neural Plast. 2013:456857.

Fischer, M., and Saver, J. L. (2015). Future directions of acute ischaemic stroke pathobiology: new insights and future directions. Int. J. Mol. Sci. 18:496. doi: 10.3390/ijms18030496

Fugleger, L., and Boulanger, L. M. (2007). Synapse remodeling, compliments of Fisher, M., and Saver, J. L. (2015). Future directions of acute ischaemic stroke pathobiology: new insights and future directions. Int. J. Mol. Sci. 18:496. doi: 10.3390/ijms18030496

Hagemeyer, N., Hanft, K. M., Akrìditou, M. A., Unger, N., Park, E. S., Stanley, E. R., et al. (2017). Microglia contribute to normal myelinogenesis and to oligodendrocyte progenitor maintenance during adulthood. Acta Neuropathol. 134, 441–458. doi: 10.1007/s00401-017-1747-1

Hakola, H. P. (1972). Neuropsychiatric and genetic aspects of a new hereditary disease characterized by progressive dementia and lipomembranous polycystic osteodysplasia. Acta Psychiatr. Scand. Suppl. 232, 1–173.

Halassa, M. M., Fellin, T., Takano, H., Dong, J. H., and Haydon, P. G. (2007). Synaptic islands defined by the territory of a single astrocyte. J. Neurosci. 27, 6473–6477. doi: 10.1523/jneurosci.2199-07.2007

Hanisch, U. K., and Kettenmann, H. (2007). Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10, 1387–1394. doi: 10.1038/nn1997

Healy, L. M., Jung, J. H., Won, S. Y., Lin, Y. H., Toulai, H., Aljarallah, S., et al. (2017). MerTK-mediated regulation of myelin phagocytosis by macrophages generated from patients with MS. Neurobiol. Aging. 54:e402. doi: 10.1016/j.neurobiolaging.2017.09.015

Healy, L. M., Perron, G., Won, S. Y., Michell- Robinson, M. A., Rezk, A., Ludwig, S. K., et al. (2016). MerTK is a functional regulator of myelin phagocytosis by human myeloid cells. J. Immunol. 196, 3375–3384. doi: 10.4049/jimmunol.1502562

Herning, E. C., Ruefzler, C. A., Gaudinski, M. R., Hu, T. C., Latour, I. L., Hallicheck, J. M., et al. (2009). Feridx preloading permits tracking of CNS-resident macrophages after transient middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 29, 1229–1239. doi: 10.1038/jcbfm.2009.48

Hermann, D. M., Kleinschnitz, C., and Gunzer, M. (2018). Implications of polymorphonuclear neutrophils for ischemic stroke and intracerebral
hemorrhage: predictive value, pathophysiological consequences and utility as therapeutic target. *J. Neuroim munol*. 321, 138–143. doi: 10.1016/j.jneuroim.m.2018.04.015

Hsieh, C. L., Koike, M., Spusta, S. C., Niemi, E. C., Yenari, M., Nakamura, M. C., et al. (2009). A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. *J. Neurochem*. 109, 1144–1156. doi: 10.1111/j.1471-4159.2009.06042.x

Hu, X., Leak, R. K., Shi, Y., Suenaga, J., Gao, Y., Zheng, P., et al. (2015). Microglial and macrophage polarization-new prospects for brain repair. *Nat. Rev. Neuro*ol. 11, 56–64. doi: 10.1038/nrneurol.2014.207

Hu, X., Li, M., Guo, Y., Wang, H., Leak, R. K., Chen, S., et al. (2012). Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. *Stroke* 43, 3063–3070. doi: 10.1161/STROKEAHA.112.659656

Huang, S., Ge, X., Yu, J., Han, Z., Yin, Z., Li, Y., et al. (2018). Increased miR-124-3p in microglial exosomes following traumatic brain injury inhibits neuronal inflammation and contributes to neurite outgrowth via their transfer into neurons. *FASEB J*. 32, 512–528. doi: 10.1096/fj.201700673R

Iadecola, C., and Anrather, J. (2011). The immunology of stroke: from mechanisms to translation. *Nat. Med.* 17, 796–808. doi: 10.1038/nm.2399

Jiang, M., Wang, H., Jin, M., Yang, X., Ji, H., Jiang, Y., et al. (2018). Exosomes from MiR-30D-5p-ADCs reverse acute ischemic stroke-induced, autophagy-mediated brain injury by promoting M2 microglial/macrophage polarization. *Cell Physiol. Biochem*. 47, 864–878. doi: 10.1159/000490078

Jin, Q., Cheng, J., Liu, Y., Wu, J., Wang, X., Wei, S., et al. (2014). Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke. *Brain Behav. Immun.* 40, 131–142. doi: 10.1016/j.bbi.2014.03.003

Kan, M. J., Lee, J. E., Wilson, J. G., Everhart, A. L., Brown, C. M., Hoofnagle, A. N., et al. (2015). Arginine deprivation and immune suppression in a mouse model of Alzheimer’s disease. *J. Neurosci*. 35, 5969–5982. doi: 10.1523/JNEUROSCI.4668-14.2015

Kawabori, M., Kacimi, R., Kauppinen, T., Calosing, C., Kim, J. Y., Hsieh, C. L., et al. (2015). Triggering receptor expressed on myeloid cells 2 (TREM2) deficiency attenuates phagocytic activities of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke. *Brain Behav. Immun.* 35, 3384–3396. doi: 10.1016/j.bbi.2015.02.028

Kettenmann, H., Hanisch, U. K., Noda, M., and Verkhratsky, A. (2011). Physiology of microglia. *Physiol. Rev.* 91, 461–553. doi: 10.1152/physrev.00011.2010

Kierdorf, K., Erny, D., Goldmann, T., Sander, V., Schulz, C., Perdiguero, E. G., et al. (2013). Microglia emerge from erythromyeloid precursors via Pu.1-dependent pathways. *J. Neurosci*. 33, 3384–3396. doi: 10.1523/JNEUROSCI.1117-12.2012

Klebe, K., Volbracht, K., Bill, E., Schneider, R., Riös, N., Hildebrandt, T., et al. (2017). Iron-sulfur glutaredoxin 2 protects oligodendrocytes against damage induced by nitric oxide release from activated microglia. *Glia* 65, 1521–1534. doi: 10.1002/glia.23178

Li, M., Li, Z., Ren, H., Jin, W. N., Wood, K., Liu, Q., et al. (2017). Colony stimulating factor 1 receptor inhibition eliminates microglia and attenuates brain injury after intracerebral hemorrhage. *J. Cereb. Blood Flow Metab.* 37, 2383–2395. doi: 10.1177/0271203X16666551

Li, P., Tan, C., Sun, B. L., Zhang, F., Lu, B., Gao, Y., et al. (2013a). Adaptive regulatory T-cell therapy protects against cerebral ischemia. *Amn. Neurol.* 74, 478–481. doi: 10.1002/ana.23815

Li, P., Mao, L., Zhou, G., Leak, R. K., Sun, B. L., Chen, J., et al. (2013b). Adoptive regulatory T-cell therapy preserves systemic immune homeostasis after cerebral ischemia. *Stroke* 44, 3509–3515. doi: 10.1161/STROKEAHA.113.002637

Li, Y., Lu, B., Sheng, L., Zhu, Z., Sun, H., Zhou, Y., et al. (2018a). Hexokinase 2-dependent hyperglycolysis driving microglial activation contributes to ischemic brain injury. *J. Neurochem*. 144, 186–200. doi: 10.1111/jncc.20146

Li, Y., Zhu, Z. Y., Huang, T. T., Zhou, Y. X., Wang, X., Yang, L. Q., et al. (2018b). The peripheral immune response after stroke-A double edge sword for blood-brain barrier integrity. *CNS Neurosci. Ther.* 24, 1115–1128. doi: 10.1111/cns.13081

Liu, C., Wu, C., Yang, Q., Gao, J., Li, L., Yang, D., et al. (2016). Macrophages mediate the repair of brain vascular rupture through direct physical adhesion and mechanical traction. *Immunity* 44, 1162–1176. doi: 10.1016/j.immuni.2016.03.008

Liu, J., Hjorth, E., Zhu, M., Calzarossa, C., Samuelsson, E. B., Schultzberg, M., et al. (2013). Interplay between human microglia and neural stem/progenitor cells in an allogeneic co-culture model. *J. Cell. Med. Mol.* 17, 1344–1443. doi: 10.1111/cmm.12123

Liu, P. S., and Ho, P. C. (2018). Mitochondria: a master regulator in macrophage and T cell immunity. *Mitochondrion* 41, 45–50. doi: 10.1016/j.mito.2017.11.002

Liu, X., Liu, J., Zhao, S., Zhang, H., Cai, W., Cai, M., et al. (2016). Interleukin-4 is essential for microglia/macrophage m2 polarization and long-term recovery after cerebral ischemia. *Stroke* 47, 498–504. doi: 10.1161/STROKEAHA.115.012079

Lyons, A., Lynch, A. M., Downer, E. J., Hanley, R., O’sullivan, J. B., Smith, A., et al. (2009). Fractaline-induced activation of the phosphatidylinositol 3 kinase pathway attenuates microglial activation in vivo and in vitro. *J. Neurochem*. 110, 1547–1556. doi: 10.1111/j.1471-4159.2009.0253x

Ma, Y., Li, Y., Jiang, L., Wang, L., Jiang, Z., Wang, Y., et al. (2016). Macrophage depletion reduced brain injury following middle cerebral artery occlusion in mice. *J. Neuroinflammations* 13:38. doi: 10.1186/s12974-016-0504-z

Ma, Y., Liu, Y., Zhang, Z., and Yang, G. Y. (2019). Significance of complement system in ischemic stroke: a comprehensive review. *Aging Dis.* 10, 429–462. doi: 10.14336/AD.2019.0119

Magnusson, J. P., Goritz, C., Tatarishvili, J., Dias, D. O., Smith, E. M., Lindvall, O., et al. (2014). A latent neurogenic program in astrocytes regulated by Notch signaling in the mouse. *Science* 346, 237–241. doi: 10.1126/science.346.6206.237

Mantovani, A., Biswas, S. K., Gallardi, M. R., Sica, A., and Locati, M. (2013). Macrophage plasticity and polarization in tissue repair and remodelling. *J. Pathol.* 229, 176–185. doi: 10.1002/path.4133

Mao, L., Li, P., Zhu, W., Cai, W., Liu, Z., Wang, Y., et al. (2017). Regulatory T cells ameliorate tissue plasminogen activator-induced brain haemorrhage after stroke. *Brain* 140, 1914–1931. doi: 10.1093/brain/awx111
Mehta, M. M., Weinberg, S. E., and Chandel, N. S. (2017). Mitochondrial control of immunity: beyond ATP. Nat. Rev. Immunol. 17, 608–620. doi: 10.1038/nri.2017.66

Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., and Hill, A. M. (2000). M1/M2 macrophages and the Th1/Th2 paradigm. J. Immunol. 164, 6166–6173. doi: 10.4049/jimmunol.164.12.6166

Milne, S. A., Mcgregor, A. L., Mcculloch, J., and Sharkey, J. (2005). Increased effect of BCG vaccination and enriched environment promote neurogenesis. J. Neuroinflammation 14:32. doi: 10.1186/s12974-017-0808-7

Ransohoff, R. M. (2016). A polarizing question: do M1 and M2 microglia exist? Nat. Neurosci. 19, 987–991. doi: 10.1038/nn.4338

Rotschenker, S. (2003). Microglia and macrophage activation and the regulation of complement-receptor-3 (CR3/MAC-1)-mediated myelin phagocytosis in injury and disease. J. Mol. Neurosci. 21, 65–72. doi: 10.1385/jmn:21:1:65

Rufino-Ramos, D., Albuquerque, P. R., Carmona, V., Perfeito, R., Nobre, R. J., and Pereira De Almeida, L. (2017). Extracellular vesicles: novel promising delivery systems for therapy of brain diseases. J. Control Release 262, 247–258. doi: 10.1016/j.jconrel.2017.07.001

Sanberg, P. R., Park, D. H., Kuzmin-Nichols, N., Cruz, E., Hossne, N. A. Jr., Bufollo, E., et al. (2010). Monocyte transplantation for neural and cardiovascular ischemia repair. J. Cell. Mol. Med. 14, 553–563. doi: 10.1111/j.1556-9822.2009.00903.x

Sandvig, I., Aug gast, I. L. H., Baberg, A. K., and Sandvig, A. (2018). Neuroplasticity in stroke recovery. The role of microglia in engaging and modifying synapses and networks. Eur. J. Neurosci. 47, 1414–1428. doi: 10.1111/ejn.13959

Sasaki, A., Kakita, A., Yoshida, K., Konno, T., Ikeuchi, T., Hayashi, S., et al. (2015). Variable expression of microglial DAP12 and TREM2 genes in Nasu-Hakola disease. Neurogenetics 16, 265–276. doi: 10.1007/s10048-015-0451-3

Schmidt, A., Streeker, J. K., Huckle, S., Bruckmann, N. M., Herold, M., Mack, M., et al. (2017). Targeting different monocyte/macrophage subsets has no impact on outcome in experimental stroke. Stroke 48, 1061–1069. doi: 10.1161/STROKEAHA.116.015577

Shibata, M., and Suzuki, N. (2017). Exploring the role of microglia in cortical spreading depression in neurological disease. J. Cerebr. Blood Flow Metab. 37, 1182–1191. doi: 10.1007/s00458-017-1690-0

Shichita, T., Ito, M., Morita, R., Komai, K., Noguchi, Y., Ooboshi, H., et al. (2017). MAFB prevents excess inflammation after ischemic stroke by accelerating clearance of damage signals through MSR1. Nat. Med. 23, 723–732. doi: 10.1038/nm.4312

Shichita, T., Ito, M., and Yoshimura, A. (2014). Post-ischemic inflammation regulates neural damage and protection. Front. Cell Neurosci. 8:319. doi: 10.3389/fncel.2014.00319

Shin, J. A., Kim, Y. A., Kim, H. W., Kim, H. S., Lee, K. E., Kang, J. L., et al. (2018). Iron released from reactive microglia by noggin improves myelin repair in the ischemic brain. Neuropharmacology 133, 202–215. doi: 10.1016/j.neuropharm.2018.01.038

Siniscalchi, A., Iannacchero, R., Anticoli, S., Pezzella, F. R., De Sarro, G., and Gallelli, L. (2016). Anti-inflammatory strategies in stroke: a potential therapeutic target. Curr. Vasc. Pharmacol. 14, 98–105. doi: 10.2174/157016113666615092311329

Smith, C. J., Denes, A., Tyrrell, P. J., and Di Napoli, M. (2015). Phase II anti-inflammatory and immune-modulating drugs for acute ischemic stroke. Expert Opin. Investig. Drugs 24, 623–643. doi: 10.1517/13543784.2015.1020110

Spalding, K. L., Bergmann, O., Alkass, K., Bernard, S., Salehpour, M., Huttner, H. B., et al. (2013). Dynamics of hippocampal neurogenesis in adult humans. Cell 153, 1219–1227. doi: 10.1016/j.cell.2013.05.002

Stamova, B., Ander, B. P., Jickling, G., Hamade, F., Durocher, M., Zhan, X., et al. (2018). Intrasubcortical hemorrhage blood transcriptome in humans differs from the ischemic stroke and vascular risk factor control blood transcriptomes. J. Cereb. Blood Flow Metab. doi: 10.1177/0271678X17695535

Stein, M., Keshav, S., Harris, N., and Gordon, S. (1992). Interleukin 4 potentially enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 167, 286–292. doi: 10.1083/jem.167.1.287

Sun, P., Liu, D. Z., Jickling, G. C., Sharp, F. R., and Yin, K. J. (2018). MicroRNA-based therapeutics in central nervous system injuries. J. Cereb. Blood Flow Metab. 38, 1125–1148. doi: 10.1038/s41373-018-02110-w

Szalay, G., Martinez, B., Lenart, N., Korneyi, Z., Orsoltis, B., Judak, L., et al. (2016). Microglia protect against brain injury and their selective elimination dysregulates neuronal network activity after stroke. Nat. Commun. 7:11499. doi: 10.1038/ncomms11499

Thore, P., Arvidsson, A., Cacci, E., Ahlenius, H., Kallur, T., Darsalia, V., et al. (2006). Persistent production of neurons from adult brain stem cells during recovery after stroke. Stem Cells 24, 739–747. doi: 10.1634/stemcells.2005-0281

Zhu et al.
Thored, P., Heldmann, U., Gomes-Leal, W., Gisler, R., Darsalia, V., Taneera, J., et al. (2009). Long-term accumulation of microglia with proneurogenic phenotype concomitant with persistent neurogenesis in adult subventricular zone after stroke. Glia 57, 835–849. doi: 10.1002/glia.20810

Tsuyama, J., Nakamura, A., Ooboshi, H., Yoshimura, A., and Shichita, T. (2018). Pivotal role of innate myeloid cells in cerebral post-ischemic sterile inflammation. Semin Immunopathol. 40, 523–538. doi: 10.1007/s00281-018-0707-8

Tur, J., Vico, T., Lloberas, J., Zorrano, A., and Celada, A. (2017). Macrophages and mitochondria: a critical interplay between metabolism, signaling, and the functional activity. Adv. Immunol. 133, 1–36. doi: 10.1016-bs.ai.2016.12.001

Vahidy, F. S., Rahbar, M. H., Zhu, H., Rowan, P. J., Bambhroliya, A. B., and Savitz, S. I. (2016). Genetic deletion of CD36 enhances injury after acute neonatal stroke. Ann. Neurol. 72, 961–970. doi: 10.1002/ana.23727

Wei, C. J., Cui, P., Li, H., Lang, W. J., Liu, G. Y., and Ma, X. F. (2019). Shared genes between Alzheimer’s disease and ischemic stroke. CNS Neurosci Ther. doi: 10.1111/1347-1073.12697

Woo, M. S., Wang, X., Faustino, J. V., Derrug, N., Wendland, M. F., Zhou, P., et al. (2012). Genetic deletion of CD36 enhances injury after acute neonatal stroke. Ann. Neurol. 72, 961–970. doi: 10.1002/ana.23727

Woo, M. S., Yang, J., Beltran, C., and Cho, S. (2016). Cell surface CD36 protein in monocyte/macrophage contributes to phagocytosis during the resolution phase of ischemic stroke in mice. J. Biol. Chem. 293, 23564–23566. doi: 10.1074/jbc.m116.750018

Webb, R. L., Kaiser, E. E., Scoville, S. L., Thompson, T. A., Fatima, S., Pandya, C., et al. (2018). Human neural stem cell extracellular vesicles improve tissue and functional recovery in the murine thromboembolic stroke model. Transl Stroke Res. 9, 530–539. doi: 10.1007/s12975-017-0599-2

Webb, R. L., Kaiser, E. E., Scoville, S. L., Thompson, T. A., Fatima, S., Pandya, C., et al. (2018). Human neural stem cell extracellular vesicles improve tissue and functional recovery in the murine thromboembolic stroke model. Transl Stroke Res. 9, 530–539. doi: 10.1007/s12975-017-0599-2

Wei, C. J., Cui, P., Li, H., Lang, W. J., Liu, G. Y., and Ma, X. F. (2019). Shared genes between Alzheimer’s disease and ischemic stroke. CNS Neurosci Ther. doi: 10.1111/1347-1073.12697

Wes, P. D., Holtman, I. R., Boddeke, E. W., Moller, T., and Eggen, B. J. (2016). Next generation transcriptomics and genomics elucidate biological complexity of microglia in health and disease. Glia 64, 197–213. doi: 10.1002/glia.22866

Wuu-Andersen, I. K., Wium-Andersen, M. K., Jorgensen, M. B., and Osler, M. (2017). Anti-inflammatory treatment and risk for depression after first time stroke in a cohort of 147 487 Danish patients. J. Psychiatry Neurosci. 42, 320–330.

Xing, C., Wang, X., Cheng, C., Montaner, J., Mandeville, E., Leung, W., et al. (2014). Neuronal production of lipocalin-2 as a help-me signal for glial activation. Stroke 45, 2085–2092. doi: 10.1161/STROKEAHA.114.007533

Xiang, C., Wang, X., Cheng, C., Montaner, J., Mandeville, E., Leung, W., et al. (2014). Neuronal production of lipocalin-2 as a help-me signal for glial activation. Stroke 45, 2085–2092. doi: 10.1161/STROKEAHA.114.007533

Yamasaki, R., Lu, H., Butovsky, O., Ohno, N., Rietsch, A. M., Ciaic, R., et al. (2014). Differential roles of microglia and monocytes in the inflamed central nervous system. J. Exp. Med. 211, 1533–1549. doi: 10.1084/jem.2011.32477

Yang, B., Xi, A., Aronowski, J., and Savitz, S. I. (2016). Various cell populations within the mononuclear fraction of bone marrow contribute to the beneficial effects of autologous bone marrow cell therapy in a rodent stroke model. Transl. Stroke Res. 7, 322–330. doi: 10.1007/s12975-016-0462-x

Yang, B., Xi, A., Aronowski, J., and Savitz, S. I. (2016). Ischemic stroke may activate bone marrow mononuclear cells to enhance recovery after stroke. Stem Cells Dev. 21, 3332–3340. doi: 10.1089/scd.2012.0037

Yang, Y., Liu, H., Zhang, H., Ye, Q., Wang, J., Yang, B., et al. (2017). ST2/IL-33-mediated activation of regulatory T cells with IL-2/IL-2 antibody complex protects against transient ischemic stroke. J. Neurosci. 37, 4692–4704. doi: 10.1523/JNEUROSCI.3233-16.2017

Yuan, D., Zhao, Y., Banks, W. A., Bullock, K. M., Haney, M., Batrakova, E., et al. (2017). Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. Biomaterials 142, 1–12. doi: 10.1016/j.biomaterials.2017.07.011

Yun, H. J., Kim, E. H., and Kim, B. G. (2018). Neuron-macrophage co-cultures contribute to the beneficial effects of autologous bone marrow cell therapy. J. Vis. Exp. 30:e56920. doi: 10.3791/56920

Zagrean, A. M., Hermann, D. M., Oppri, I., Zagrean, L., and Popa-Wagner, A. (2018). Multicellular crosstalk between exosomes and the neurovascular unit after cerebral ischemia. Therapeutic implications. Front. Neurosci. 12. doi: 10.3389/fnins.2018.00811

Zhang, H., Xia, Y., Ye, Q., Yu, F., Zhu, W., Li, P., et al. (2018). In vivo expansion of regulatory T cells with IL-2/IL-2 antibody complex protects against transient ischemic stroke. J. Neurosci. 38, 10166–10179. doi: 10.1523/JNEUROSCI.3411-17.2018

Zhao, S. C., Ma, L. S., Chu, Z. H., Xu, H., Wu, W. Q., and Liu, F. (2017). Regulation of microglial activation in stroke. Acta Pharmacol. Sin. 38, 445–458. doi: 10.1038/aps.2016.162

Zhang, H., Xia, Y., Ye, Q., Yu, F., Zhu, W., Li, P., et al. (2018). In vivo expansion of regulatory T cells with IL-2/IL-2 antibody complex protects against transient ischemic stroke. J. Neurosci. 38, 10166–10179. doi: 10.1523/JNEUROSCI.3411-17.2018

Zhao, S. C., Ma, L. S., Chu, Z. H., Xu, H., Wu, W. Q., and Liu, F. (2017). Regulation of microglial activation in stroke. Acta Pharmacol. Sin. 38, 445–458. doi: 10.1038/aps.2016.162

Zhang, H., Xia, Y., Ye, Q., Yu, F., Zhu, W., Li, P., et al. (2018). In vivo expansion of regulatory T cells with IL-2/IL-2 antibody complex protects against transient ischemic stroke. J. Neurosci. 38, 10166–10179. doi: 10.1523/JNEUROSCI.3411-17.2018

Zhao, S. C., Ma, L. S., Chu, Z. H., Xu, H., Wu, W. Q., and Liu, F. (2017). Regulation of microglial activation in stroke. Acta Pharmacol. Sin. 38, 445–458. doi: 10.1038/aps.2016.162

Zhu et al. Targeting Myeloid Cells in Stroke
experimentally induced photothrombotic stroke. *J. Cereb. Blood Flow Metab.* 37, 3709–3724. doi: 10.1177/0271678X17696100

Zheng, H., Jia, L., Liu, C. C., Rong, Z., Zhong, L., Yang, L., et al. (2017). TREM2 promotes microglial survival by activating Wnt/beta-Catenin pathway. *J. Neurosci.* 37, 1772–1784. doi: 10.1523/JNEUROSCI.2459-16.2017

Zheng, Y., He, R., Wang, P., Shi, Y., Zhao, L., and Liang, J. (2019). Exosomes from LPS-stimulated macrophages induce neuroprotection and functional improvement after ischemic stroke by modulating microglial polarization. *Biomater Sci.* 7, 2037–2049. doi: 10.1039/c8bm01449c

Zhu, W., Fan, Y., Hao, Q., Shen, F., Hashimoto, T., Yang, G. Y., et al. (2009). Posts ischemic IGF-1 gene transfer promotes neurovascular regeneration after experimental stroke. *J. Cereb. Blood Flow Metab.* 29, 1528–1537. doi: 10.1038/jcbfm.2009.75

Ziv, Y., Ron, N., Butovsky, O., Landa, G., Sudai, E., Greenberg, N., et al. (2006). Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. *Nat. Neurosci.* 9, 268–275. doi: 10.1038/nn1629

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Zhu, Zheng, Li, Huang, Chao, Pan, Zhu, Zhao, Yu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.